These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38895622)

  • 1. Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review.
    Gu X; Zhong Y; Huang H
    Front Pharmacol; 2024; 15():1410684. PubMed ID: 38895622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
    Kanaji N; Ichihara E; Tanaka T; Ninomiya T; Kozuki T; Ishikawa N; Nishii K; Shoda H; Yamaguchi K; Kawakado K; Toyoda Y; Inoue M; Miyatake N; Watanabe N; Inoue T; Mizoguchi H; Komori Y; Kojima K; Kadowaki N
    Lung; 2024 Feb; 202(1):63-72. PubMed ID: 38265672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.
    Li MSC; Lee KWC; Mok KKS; Loong HHF; Lam KC; Mok FST; Chan LL; Lau YM; Chan KP; Ng JTY; Wong WKY; Lam BHW; Chen ACC; Lee MMP; Chen OH; Mok TSK
    JTO Clin Res Rep; 2024 Apr; 5(4):100648. PubMed ID: 38590729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
    Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
    Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report.
    Takakuwa O; Oguri T; Uemura T; Sone K; Fukuda S; Okayama M; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Maeno K; Niimi A
    Mol Clin Oncol; 2017 Sep; 7(3):383-385. PubMed ID: 28808573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
    Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
    Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report.
    Sato Y; Sekine A; Hagiwara E; Sato M; Yamaya T; Asaoka M; Higa K; Ikeda S; Baba T; Komatsu S; Iwasawa T; Ogura T
    Respir Med Case Rep; 2021; 33():101450. PubMed ID: 34401289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
    Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
    Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of Switching EGFR-TKIs for Advanced Lung Adenocarcinoma Due to Interstitial Lung Disease: A Case Report.
    Zeng X; Wang T; Tang Y; Liao X; Wang J; Li Y
    Curr Cancer Drug Targets; 2024 Jul; ():. PubMed ID: 38982693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
    Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody.
    Mamesaya N; Kenmotsu H; Katsumata M; Nakajima T; Endo M; Takahashi T
    Invest New Drugs; 2017 Feb; 35(1):105-107. PubMed ID: 27599705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
    Nishima S; Miyanaga A; Saito S; Yuasa M; Takahashi S; Kashiwada T; Sugano T; Noro R; Minegishi Y; Terasaki Y; Saito Y; Kubota K; Seike M; Gemma A
    Intern Med; 2021 Feb; 60(4):591-594. PubMed ID: 32999231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease.
    Wang H; Zhang L; Shi X; Zhang X; Si X
    Onco Targets Ther; 2019; 12():5545-5549. PubMed ID: 31371992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
    Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T
    Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis.
    Mohammed T; Mangeshkar S; Rathmann J
    Case Rep Oncol; 2021; 14(2):733-738. PubMed ID: 34177523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal interstitial lung disease associated with icotinib.
    Zhang J; Zhan Y; Ouyang M; Qin Y; Zhou C; Chen R
    J Thorac Dis; 2014 Dec; 6(12):E267-71. PubMed ID: 25590006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality.
    Zhou Q; Hu Z; Li X; Tang X
    BMC Pulm Med; 2023 Mar; 23(1):79. PubMed ID: 36890493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.